Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NUVB
NUVATION BIO INC.
NYSE
$6.66
▼ DOWN 4.72% (-0.33)

KEY STATISTICS

Market Cap$2.31 B
52w High$9.75
52w Low$2.91
Dividend Yield—
Frequency—
P/E-16.24
Volume3.66M
Shares Out.347.20M

COMPANY

LEADERSHIP

David T. Hung
CHIEF EXECUTIVE
David T. Hung

COMPENSATION 2026

Salary$650,016
Stock Awards$0
Incentive Plan Pay$536,250
All Other Comp.$15,834
Total$3,876,736

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 26, 2020
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
305

PRICE TARGET

Target High$21.00
Target Low$20.00
Target Median$20.50
Target Consensus$20.50

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.$35.77M
NOV
2
MON

PRICE

$6.66 ▼ DOWN 4.72% (−$0.33)
$6.70$6.80$6.909:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM6.66

About Nuvation Bio Inc.

https://www.nuvationbio.com ↗

Nuvation Bio Inc. is a New York-based clinical-stage biopharmaceutical company developing oncology therapeutics, including CDK, BET, Wee1, adenosine receptor inhibitors, and PARP-targeting platforms.

INDUSTRY

Biotechnology

A PRODUCT NUVATION BIO INC. IS KNOWN FOR

IBTROZI™ (taletrectinib)
IBTROZI™ (taletrectinib)

IBTROZI™ is an FDA-approved oral ROS1 TKI for treating advanced ROS1-positive NSCLC, marking Nuvation Bio's shift to a commercial-stage company with its flagship marketed product.

COMPETITORS

COMPETITOR
BMY COMPARE
LLY COMPARE
MRK COMPARE
NU NUVL COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q4-2025Q1-2026Q2-2026
Product$1.24M $23.43M ▲$18.51M ▼$23.19M ▲
License$3.6M $34.64M ▲$64.72M ▲$8.49M ▼

Revenue by Geography

MapREGIONQ2-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$1.24M $23.46M ▲$77.39M ▲$23.19M ▼
CHINA$3.4M $3.11M ▼$5.19M ▲$7.99M ▲
JAPAN$241K $28.39M ▲$652K ▼$504K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
124
LISTED HERE
24
RANKED BY POSITION SIZE
VTS.AX
0.00% · 8.9M
IWM
0.06% · 6.5M
XPH
2.17% · 1.8M
SCHA
0.04% · 1.2M
FYC
0.47% · 984.3K
DFMC
0.08% · 956.1K
PTH
1.07% · 431.9K
SBIO
1.19% · 429.5K
CANC
1.31% · 416.6K
BBP
1.74% · 297.6K
NUSC
0.12% · 259.9K
XRSU.L
0.06% · 230.6K
RSSL
0.06% · 120.3K
FHLC
0.02% · 116.1K
PILL
1.46% · 51.3K
GSSC
0.03% · 48.4K
ACSG
0.31% · 23.2K
RTWP.L
0.05% · 15.3K
URTY
0.02% · 10.2K
ESSC
0.17% · 10.2K
RFLR
0.06% · 8.9K
TILT
0.00% · 5.3K
AVSC
0.00% · 2.5K
USFMDN.MX
0.00% · 1.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
53.07%
HOLDERS
314
TOP 12 OF 314 · RANKED BY POSITION SIZE
Fmr LLC
52.2M sh · $296.67M
Blackrock, Inc.
27.6M sh · $156.94M
Decheng Capital LLC
26.0M sh · $147.42M
Blackrock Inc.
16.2M sh · $47.41M
Vanguard Group Inc
15.6M sh · $139.38M
Laurion Capital Management LP
10.2M sh · $19.97M
Omega Fund Management, LLC
8.8M sh · $32.68M
State Street Corp
7.4M sh · $41.87M
Geode Capital Management, LLC
6.2M sh · $35.48M
Millennium Management LLC
4.9M sh · $17.95M
Nuveen, LLC
4.6M sh · $16.9M
Duquesne Family Office LLC
4.5M sh · $25.79M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Hattersley Gary
Sale · 100.0K shares
2026-08-19
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Hattersley Gary
Purchase · 100.0K shares
2026-08-19
★
OFFICER: CHIEF FINANCIAL OFFICER
Sauvage Philippe
Purchase · 40.0K shares
2026-07-15
★
OFFICER: CHIEF FINANCIAL OFFICER
Sauvage Philippe
Sale · 40.0K shares
2026-07-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
BUY 2
NEUTRAL 1
MARKET OUTPERFORM 1
6 GRADES IN THE LAST 12 MONTHS
RBC Capital OUTPERFORM HC Wainwright & Co. BUY Wedbush OUTPERFORM Truist Securities BUY UBS NEUTRAL Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
EWTX$42.76COMPARE
ABCL$11.35COMPARE
QURE$48.72COMPARE
GPCR$47.37COMPARE
VRDN$23.08COMPARE
CLDX$39.12COMPARE
VERA$34.19COMPARE
OCUL$10.36COMPARE